The first anniversary issue.

It has been 1 year since the first issue of Neurology ® Neuroimmunology & Neuroinflammation (N2) was launched. Since then, there has been a steady growth in the number of manuscripts received and an increasing number of manuscripts included in each bimonthly issue. The current issue contains 26 manuscripts: 6 related to multiple sclerosis (MS), 7 to antibody-associated encephalitis, 3 to aquaporin-4 (AQP4) antibody–related disorders, and 10 to other inflammatory or autoimmune neurologic disorders. Three of these manuscripts are updates on optic neu-ritis, AQP4 autoimmunity, and biomarkers of neuro-myelitis optica. Bridel et al. 1 investigated the hematologic modifications in the peripheral blood of 44 patients with relapsing-remitting MS treated with natalizumab for 18 months. They found that the mean total white blood cell, lymphocyte, and eosinophil counts were significantly higher 1 month after treatment initiation and remained stable thereafter. In contrast, the mon-ocyte counts increased progressively during the 18-month treatment. In addition, erythroblasts and neutrophil precursors that were absent before treatment initiation became evident in 16% and 6.8% of patients, respectively, 1 month after treatment onset. None of these changes were associated with malig-nancy, although longer follow-up is needed to rule out this possible complication. Recognition of these changes in patients treated with natalizumab prevents unnecessary diagnostic procedures. In another study, Pérez-Miralles et al. 2 investigated the association between brain volume loss during the first year of interferon treatment and clinical outcome at 4 years in patients with MS. They found that whole-brain and white matter volume changes in the first year of treatment were independent predictors of worsening disability. Among the manuscripts focused on antibody-associated encephalitis, Hilderink et al. 3 describe a newborn with anti–NMDA receptor (NMDAR) encephalitis due to intrauterine transfer of maternal NMDAR antibodies. The mother did not have active disease during pregnancy (she had had anti-NMDAR encephalitis 4 years earlier), and no other problems occurred during the pregnancy. The child improved spontaneously along with a progressive decrease of antibody titers. This represents the first unambiguous case of anti-NMDAR encephalitis in a newborn. Elamin et al. 4 describe a patient with